The Federal Trade Commission is being urged to investigate the business practices of pharmacy benefit managers now that there’s a new Democratic-appointed FTC commissioner who could break a deadlock that in February blocked an FTC probe of the PBM industry’s impact on drug prices . The Pharmaceutical Care Management Association says PBMs are just one part of the drug supply chain and if the FTC looks into PBM practices, it should investigate the other sectors, too. A vote on whether...